The hip replacement market is beginning to recover from the global recession and controversies surrounding metal-on-metal implants, with procedure volumes growing and patient confidence at an all-time high. According to GlobalData, approximately 1.7 million hip replacement procedures, including partial, primary, revision and resurfacing, were performed across the globe in 2013, and this figure is expected to increase to 2.5 million by 2020.
Yoshiki Sasai, a senior Japanese scientist embroiled in a stem-cell research scandal died Tuesday in an apparent suicide, police said. Sasai, who supervised and co-authored stem-cell research papers that had to be retracted due to falsified contents, was found suffering from cardiac arrest at the government-affiliated science institute RIKEN in Kobe, in western Japan, according to Hyogo prefectural police.
J-Plasma is a transformational, helium-based, gas plasma technology that offers remarkably low thermal spread, a high level of precision with versatility across multiple surgical specialties.
The Medline Unite Cannulated Screw System provides a complete selection of implants and instrumentation with intuitive color-coding and the contents are organized in the order in which each item is used. It is the only color-coded, star-driven, cannulated screw system on the market that offers both headed and headless screws in one convenient tray.
Baxter International announced that the FDA has approved FLEXBUMIN [Albumin (Human)], USP, 5% Solution. FLEXBUMIN 5% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns and in patients undergoing cardiopulmonary bypass surgery. The FLEXBUMIN 5% solution will be available to U.S. customers later this year. FLEXBUMIN is the first and only preparation of human albumin to be packaged in a flexible plastic container.
Research is taking place in transcranial ultrasound therapy, which in the future can potentially be applied to the treatment of brain tumours and targeted drug delivery. The therapy modality has already been successfully applied to the treatment of neuropathic pain disorder and essential tremors. The study focuses on two issues: skull-base heating and formation of standing-waves.
Neuralstem, Inc. announced that the final patient was treated in its Phase II trial using spinal cord-derived neural stem cells in the treatment of Lou Gehrig's disease. "The completion of Phase II of this important clinical research program is a major milestone, demonstrating that patients can tolerate the transplantation of high doses of cells and multiple spinal cord injections," said site principal investigator, Jonathan D. Glass, MD.
The use of electronic reminders is highly effective at getting surgical patients to adhere to a preadmission antiseptic showering regimen known to help reduce risk of surgical site infections (SSIs). Each year about 400,000 SSIs occur and lead to a death rate of nearly 100,000. To reduce the risk of infections, clinicians recommend that patients take antiseptic showers with chlorhexidine gluconate (CHG) 24 to 48 hours before admission.
The delicate separation 10 years ago of conjoined twins from the Philippines wasn't perfect, but the boys' mother says their very survival is reason enough to celebrate the anniversary. The boys were separated on Aug. 4, 2004, in an operation that climaxed a then-unusual "staged separation" that took four surgeries over nine months.
The Nuvo Vu is an LED surgical light with features that include a 160,000 lux, 4,300-degree K color temperature and 95 CRI.
ArtVentive Medical Group announced excellent clinical results in conjunction with expanded enrollment in the ArtVentive Endoluminal Occlusion System, OCCLUDE I post-market surveillance study. In conjunction with the study, four female patients were treated for pelvic congestion syndrome and seven male patients were treated for varicoceles using the ArtVentive EOS™ device.
Crosstex offers their Rapicide OPA/28 High Level Disinfectant, which the company describes as providing a superior way to reprocess heat-sensitive, semi-critical medical devices that are unsuitable for sterilization.
“We are excited about the progress of our lead nanotechnology-based program, LE-MPP, with four active clinical trials,” said Kim Brazzell, Ph.D., Chief Medical Officer of Kala. “With the initiation of our latest trial in RVO and DME, Kala is making significant progress toward demonstrating the unique ability of Kala’s MPP platform to deliver drugs to the back of the eye following topical administration.”
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation announced that OncoCyte has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. OncoCyte’s initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with a reputation for excellence and discovery.
Steris feels their SignatureSuite, a component of the Harmony iQ OR Integration System, transforms the OR into a serene environment through personalized images, as well as customized music and room settings.